TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06756178

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol Group 1
Description: Postoperative Use:~Bolus: 10-20 mg intravenously as needed for sedation initiation. Continuous infusion: 0.3-0.5 mg/kg/hour to maintain light sedation adjusted based on clinical response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Intervention
Description: Postoperative Use:~Initial bolus: 5 mg intravenously upon ICU arrival. Continuous infusion: 0.2-0.3 mg/kg/hour to maintain light sedation with a maximum dose of 0.8 mg/kg/hour.~Rescue sedation with propofol or midazolam will be allowed if patients become agitated or if Remimazolam is ineffective in maintaining target sedation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Intervention
Description: Postoperative Use:~Loading dose: 0.5-1 μg/kg over 10-20 minutes after ICU arrival. Continuous infusion: 0.2-0.7 μg/kg/hour for sedation maintenance, adjusted as needed to maintain light sedation.~Rescue sedation with propofol or midazolam will be administered if Dexmedetomidine fails to maintain adequate sedation or if patients become agitated.
Study: NCT06753578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: Acceptance and Commitment Therapy (ACT); Quality of Life (QOL); Mild Cognitive Impairment (MCI); cognitive function; elderly; psychological flexibility.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: standard care
Study: NCT06752278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pilocarpine
Description: Pilocarpine is a muscarinic agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artificial tears
Description: artificial tears used for the treatment of Dry eye
Study: NCT06755047

Intervention type: RADIATION
Intervention: 3D Ultrasound
Description: 3D placental volume and vascular indices

Intervention type: RADIATION
Intervention: 2D ultrasound
Description: 2D placental criteria of invasion and color Doppler
Study: NCT06752161

Intervention type: OTHER
Intervention: Urine analysis
Description: Urine analysis and culture for Screening and diagnostic tools for UTI in pregnant women
Study: NCT06754371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: intravenous infusion of tranexamic acid 1g (20ml) 10min before skin dissection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: intravenous infusion of normal saline 20ml 10min before skin dissection
Study: NCT06752668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORX750
Description: ORX750 capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORX750
Description: ORX750 capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORX750
Description: ORX750 capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: ORX750 matching placebo capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: ORX750 matching placebo capsule.
Study: NCT06091800

Intervention type: OTHER
Intervention: biochemical analysis
Description: GCF and serum samples were collected from the participants for biochemical analysis.

Intervention type: OTHER
Intervention: biochemical analysis
Description: GCF and serum samples were collected from the participants for biochemical analysis.
Study: NCT06417606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib（oral，12mg once daily if body weight ≥60Kg; Body weight \< 60Kg, 8mg/ day）； Adebrelimab（intravenous drip，1200mg once every 3 weeks）； GEMOX（intravenous drip，Gemcitabine 1000mg/m2, 2 times every 3 weeks d1+d8; intravenous drip，Oxaliplatin, 100mg/m2, was given every 3 weeks）
Study: NCT06546397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17β-estradiol/dydrogesterone tablets
Description: The medication group began taking 17β-estradiol/dydrogesterone tablets orally for 28 days starting from the first day after induced abortion surgery (taking 2mg of 17β-estradiol orally once a day for the first 14 days, and then taking 2mg of 17β-estradiol + 10mg of dydrogesterone tablets orally once a day for the next 14 days). The blank control group did not take any medication.
Study: NCT06540729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab vedotin in combination with AK104 and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer
Description: Disitamab vedotin (RC48) in combination with AK104 (PD-1/CTLA-4 bispecific) and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer
Study: NCT05250349

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Transthoracic echocardiography with standard measurements

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Transthoracic echocardiography with standard measurements

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Transthoracic echocardiography with standard measurements

Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler sonography
Description: Transcarotid and transcranial Doppler sonography

Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler sonography
Description: Transcarotid and transcranial Doppler sonography
Study: NCT06752668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: ORX750 matching placebo capsule.
Study: NCT06755996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine injection
Description: Dexmedetomidine injection 3μg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam
Description: remimazolam 0.5mg / kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: remimazolam 0.5mg / kg
Study: NCT06754046

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RP-MUS
Description: a standard urethral sling placement for treatment of stress urinary incontinence
Study: NCT05250349

Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler sonography
Description: Transcarotid and transcranial Doppler sonography

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA)
Study: NCT05718388

Intervention type: OTHER
Group type: OTHER
Intervention: Physical therapy exercises
Description: For two consecutive months, the children in control group underwent a physiotherapy program for 60min/ three sessions each week: it was based mainly on the neurodevelopment technique, directed toward inhibiting abnormal muscle tone facilitating normal patterns of postural control and hand functions training program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isokinetic training
Description: Children in study group received the same program given to control group (A) in addition to isokinetic resistance training of the less affected upper limb for shoulder abductors in concentric mode at the angular velocity of 180 degree/ second under full supervision on the Biodex isokinetic dynamometer three times per week for 8 weeks, making a total of 24 training sessions. Each child was trained in the seated position with the similar precaution of the testing protocol.
Study: NCT04854512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin DR
Description: Delay-Release Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin IR
Description: Immediate Release Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin DR Placebo
Description: Metformin DR Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin DR Placebo
Description: Metformin DR Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR placebo
Description: Metformin IR placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin IR placebo
Description: Metformin IR placebo
Study: NCT05687396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: virtual reality designed as cycling in the forest
Study: NCT05342090

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured Counselling Tool
Description: Participants will be administered a Structured Counselling Tool that addresses the following themes: outside influences, conflicting emotions, uncertainty, sexual changes and stability, normalization, self-image
Study: NCT05687396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional pulmonary rehabilitation
Description: pulmonary rehabilitation
Study: NCT05033717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue Flossing Technique
Description: Subjects will receive tissue-flossing intervention on bicep muscle for 30 sec to 2 min with an occlusion pressure of 100 mmHg.~After removal of flossing, participants will perform bicep strengthening exercises at an intensity of 30% of 1 RM with 6-8 rep, 4 sets for a single day and 3 days per week for 2 weeks in total.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretching Technique
Description: Subjects will perform passive static stretching exercises of bicep muscle. Each stretch will last for 30 sec at 100% of stretch intensity with 4 reps for each, 1 set per day and 3 days per week for total duration of two weeks.~After the application of static stretch, participants will perform bicep strengthening exercises at an intensity of 30% of 1 RM with 6-8 reps, 4 sets for a single day and 3 days per week for 2 weeks in total.
Study: NCT05579470

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NIATx
Description: For each country, the learning collaborative will be comprised of a Chief Narcologist from each region where the investigators will initially train them and the coaches using all the tools from the NIATx Academy (2-3-day training). The national coach for each country will receive ongoing and in-depth coaching from a US-based super coach. A nationwide Nominal Group Technique (NGT) will be conducted to assess barriers and potential targets to guide decision-making about changes. At the end of the initial meeting, each Chief Narcologist (CN) will be able to identify a change target for Plan, Do, Study, Act (PDSA) (entry, retention) and create a Change Project Form to state what will be done (e.g. flowcharting), who is involved (team), what are the measures and timeframe (\<4 weeks).
Study: NCT03812016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic device
Description: The device comprises 1 or 2 matched pairs of one near-infrared light-emitting diode (SMT910, Epitex Inc, Kyoto, Japan) and one sensor (PD15-22C TR8, Everlight Electronics Corporation, New Taipei City, Taiwan), a permanent electromagnetic actuator (JNP-12/12, Joint Magnetic Technology Corporation, Shenzhen, China), an iron sheet, and a biosignal acquisition module. The efficacy and safety were assessed using the magnetic device.
Study: NCT06754046

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PAHG
Description: A standard 2 mL dose injection of bulkamid (order and number will be at the discretion of the surgeon) will be given. Patients undergoing PAHG will be given sham incisions consisting of superficial suprapubic epidermal scratches with a needle and fibrin glue at expected sling exit sites.
Study: NCT06753409

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Processed electroencephalography (pEEG) Guided General Anesthesia
Description: Processed electroencephalography (pEEG) can guide the optimization of anesthesia depth, potentially preventing overly deep anesthesia and, in turn, reducing the incidence of IOH and the need for vasopressors .~Depth of anesthesia will be managed based on pEEG monitoring using Entropy with a target range of 40-60.
Study: NCT05484375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine plus toripalimab
Description: Capecitabine tablet: 650mg/m2, orally, twice a day, d1-d21, every 3 weeks Toripalimab: 240mg, intravenous drip, d1, every 3 weeks
Study: NCT05472610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BZ019
Description: A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).
Study: NCT06413628

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: screw tapered appliance
Description: The appliance was digitally designed by solid works programs for 3rd CAD design software to obtain the STL file format. The virtual design of was approved. The printerwas loaded with material of 3D-printed denture base. The appliance was printed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: screw tapered appliance
Description: The appliance was digitally designed by solid works programs for 3rd CAD design software to obtain the STL file format. The virtual design of was approved. The printerwas loaded with material of 3D-printed denture base. The appliance was printed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: screw tapered appliance
Description: The appliance was digitally designed by solid works programs for 3rd CAD design software to obtain the STL file format. The virtual design of was approved. The printerwas loaded with material of 3D-printed denture base. The appliance was printed.
Study: NCT05708118

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiographic assessment.
Description: Patients will be contacted to carry out an echocardiography at least 90 days after surgery. Measurements will be taken for aortic annulus, sinuses of Valsalva, sino-tubular junction, tubular ascending aorta. Aortic valve will be assessed as well.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiographic assessment.
Description: Patients will be contacted to carry out an echocardiography at least 90 days after surgery. Measurements will be taken for aortic annulus, sinuses of Valsalva, sino-tubular junction, tubular ascending aorta. Aortic valve will be assessed as well.

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed-tomography assessment
Description: All enrolled patients will undergo a multislice CT scan (retrospectively ECG-gated, whenever possible) with standard contrast medium injection protocol of nonionic contrast agent. All post-surgery controls will be performed at least 90 days after surgery. All CT datasets will be analysed on a dedicated workstation for the qualitative and quantitative assessment of the aortic root including measurements for aortic annulus, sinuses of Valsalva, sino-tubular junction, tubular ascending aorta.

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed-tomography assessment
Description: All enrolled patients will undergo a multislice CT scan (retrospectively ECG-gated, whenever possible) with standard contrast medium injection protocol of nonionic contrast agent. All post-surgery controls will be performed at least 90 days after surgery. All CT datasets will be analysed on a dedicated workstation for the qualitative and quantitative assessment of the aortic root including measurements for aortic annulus, sinuses of Valsalva, sino-tubular junction, tubular ascending aorta.
Study: NCT04694599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low flow oxygen
Description: Low flow oxygen delivered via nasal prong or facial mask. The flow rate is adjusted according to oxygen saturation of the patient.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low flow oxygen
Description: Low flow oxygen delivered via nasal prong or facial mask. The flow rate is adjusted according to oxygen saturation of the patient.
Study: NCT05056324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Online vestibular rehabilitation tool
Description: For those randomized to the intervention group, a 6 weeks duration vestibular rehabilitation will be delivered using an online tool (YrselTräning)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care (written instructions leaflet)
Description: For those randomized to the control group, a 6 weeks duration standard vestibular rehabilitation will be delivered using a written instructions leaflet
Study: NCT06575387

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partogram
Description: to evaluate the utility of partogram in management and progress of active labor in Primigravidae.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partogram
Description: to evaluate the utility of partogram in management and progress of active labor in Primigravidae.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partogram
Description: to evaluate the utility of partogram in management and progress of active labor in Primigravidae.
Study: NCT04409236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quit2Heal
Description: Use Quit2Heal app

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: QuitGuide
Description: Use QuitGuide app

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05705440

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: RSVPreF3 vaccine
Description: No intervention is administered in this extension study. Participants received the RSVPreF3 vaccine during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study. In all prior RSV MAT studies, participants received one dose of RSVPreF3 vaccine except in RSV MAT-011 study, where some participants received a second dose as well.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No intervention is administered in this extension study. Participants received any control (placebo, Tdap or influenza vaccine) during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study. In all prior RSV MAT studies, participants received one dose of any control (placebo, Tdap or influenza vaccine).
Study: NCT06753409

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-pEEG-Guided General Anesthesia (with blinded pEEG monitoring)
Description: Depth of anesthesia will be managed based on clinical judgment, informed by clinical perception and vital signs.
Study: NCT06751888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled CO2 delivery
Description: The use of a controlled CO2 delivery offers a straightforward way to increase arterial CO2. Controlled CO2 inhalation may offer a novel hemodynamic therapy for patients with Neurogenic Orthostatic Hypotension

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Controlled CO2 delivery (Sham)
Description: For this intervention, we will be using this device set at 0% CO2 for our sham comparison.
Study: NCT06755034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: c-SIMO
Description: Placement of an implant in the mandibular canine area and using it to stabilize a pre-existing mandibular complete denture.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: m-SIMO
Description: Placement of an implant in the midline of the mandible and using it to stabilize a pre-existing mandibular complete denture.
Study: NCT06752317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: patients will receive intrathecal dexamethasone 8 mg in 3 ml volume.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: patients will receive intrathecal dexmedetomidine 0.5 µg/kg in 3 ml volume.
Study: NCT06754839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous left ventricular assist device(Ventiflow LP)
Description: The PCI will be completed with the support of percutaneous left ventricular assist device(Ventiflow LP).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VA-ECMO
Description: The PCI will be completed with the support of Veno-arterial extracorporeal membrane oxygenation (VA-ECMO).
Study: NCT06756035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-95
Description: Weekly IV dosing
Study: NCT06755632

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TROD (rapid diagnostic orientation test) and FibroScan®
Description: Fast-track appointment at the hepatology consultation at Avicenne Hospital (Bobigny) or the hepatology consultation at Jean Verdier Hospital (Bondy) for any patient :~* with Fibroscan® ≥ 9.6 KPa or~* positive hepatitis C serology or~* HBsAg positive
Study: NCT06753747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib(30mg)
Description: Afatinib will be administered orally at a dose of 30 mg once daily (QD) in each 4-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib(40mg)
Description: Afatinib will be administered orally at a dose of 40 mg once daily (QD) in each 4-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib(RP2D)
Description: In the Phase 2 study, the recommended Phase 2 dose (RP2D) of Afatinib, determined during the Phase 1b portion, will be utilized.
Study: NCT06752174

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV+bOPV
Description: 2+1 sequential immunization program (sIPV-sIPV-bOPV)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: wIPV+bOPV
Description: 2+1 sequential immunization program (wIPV-wIPV-bOPV)
Study: NCT06752382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug
Description: Induction therapy was sintilimab 200mg IV d1, bevacizumab 7.5mg/kg IV d1, albumin-bound paclitaxel 260mg/m2 IV d1 and cisplatin 80mg/m2 IV d1, once every 3 weeks, a total of 3 cycles.
Study: NCT06756191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy group
Description: Liposomal amphotericin B (AmBisome®) combination with Isavuconazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Amphotericin B
Description: Liposomal amphotericin B (AmBisome®) alone
Study: NCT06755866

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The application value of MRI 4D Free Breathing DCE-MRI in the treatment of esophageal cancer
Description: Chest MRI scan outside of standard treatment options